Real-world study tests epcoritamab for hard-to-treat lymphoma
NCT ID NCT07393204
First seen Feb 06, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This study tracks 150 adults with relapsed or refractory diffuse large B-cell lymphoma who have already tried at least two other treatments. Researchers want to see how well epcoritamab works outside of a controlled clinical trial, focusing on tumor shrinkage and side effects. The goal is to understand the drug's real-world effectiveness and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IRCCS Ospedale San Raffaele
Milan, Italy
Conditions
Explore the condition pages connected to this study.